256 related articles for article (PubMed ID: 23328959)
1. Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Seymour N; Sawh SC
Can J Anaesth; 2013 May; 60(5):492-9. PubMed ID: 23328959
[TBL] [Abstract][Full Text] [Related]
2. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis.
Condron ME; Pommier SJ; Pommier RF
Surgery; 2016 Jan; 159(1):358-65. PubMed ID: 26603846
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks.
Borna RM; Jahr JS; Kmiecik S; Mancuso KF; Kaye AD
Anesthesiol Clin; 2017 Jun; 35(2):327-339. PubMed ID: 28526153
[TBL] [Abstract][Full Text] [Related]
4. Octreotide treatment of carcinoid hypertensive crisis.
Warner RR; Mani S; Profeta J; Grunstein E
Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
[TBL] [Abstract][Full Text] [Related]
5. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
Le BT; Bharadwaj S; Malinow AM
Int J Obstet Anesth; 2009 Apr; 18(2):182-5. PubMed ID: 19200714
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
7. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
Massimino K; Harrskog O; Pommier S; Pommier R
J Surg Oncol; 2013 Jun; 107(8):842-6. PubMed ID: 23592524
[TBL] [Abstract][Full Text] [Related]
8. Development of effective prophylaxis against intraoperative carcinoid crisis.
Woltering EA; Wright AE; Stevens MA; Wang YZ; Boudreaux JP; Mamikunian G; Riopelle JM; Kaye AD
J Clin Anesth; 2016 Aug; 32():189-93. PubMed ID: 27290972
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
10. Octreotide LAR in carcinoid: how to dose?
Yao JC; Kvols LK
Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
[No Abstract] [Full Text] [Related]
11. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours.
Welin SV; Janson ET; Sundin A; Stridsberg M; Lavenius E; Granberg D; Skogseid B; Oberg KE; Eriksson BK
Eur J Endocrinol; 2004 Jul; 151(1):107-12. PubMed ID: 15248829
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
[TBL] [Abstract][Full Text] [Related]
13. [Update on the anesthetic management of patients with malignant carcinoid syndrome].
Rodríguez-Cosmen C; Trillo Urrutia L; Pacreu Terradas S; Comps Vicente O; Escolano Villén F
Rev Esp Anestesiol Reanim; 2005 May; 52(5):291-4. PubMed ID: 15968907
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogues do not prevent carcinoid crisis.
Guo LJ; Tang CW
Asian Pac J Cancer Prev; 2014; 15(16):6679-83. PubMed ID: 25169508
[TBL] [Abstract][Full Text] [Related]
15. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
McCully BH; Kozuma K; Pommier S; Pommier RF
Ann Surg Oncol; 2024 May; 31(5):2996-3002. PubMed ID: 38227166
[TBL] [Abstract][Full Text] [Related]
17. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
18. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
Ammann M; Kinney MAO; Gudmundsdottir H; Santol J; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Anderson AL; Halfdanarson TR; Nagorney DM; Starlinger PP
Ann Surg Oncol; 2024 Jun; 31(6):3976-3977. PubMed ID: 38619707
[No Abstract] [Full Text] [Related]
20. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
